Advances in pharmacotherapy for acute kidney injury

References

• Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607–625.
   PubMed Web of Science ®Google Scholar
• Moore PK, Hsu RK, Liu KD. Management of acute kidney injury: core curriculum 2018. Am J Kidney Dis. 2018;72(1):136–148.
   PubMed Web of Science ®Google Scholar
• Vanmassenhove J, Kielstein J, Jörres A, et al. Management of patients at risk of acute kidney injury. Lancet. 2017;389(10084):2139–2151.
   PubMed Web of Science ®Google Scholar
• Baysal A, Yanartas M, Dogukan M, et al. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28(3):586–594.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Pollesello P, Vajda G, et al. Effects of levosimendan on the energy balance: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2009;53(4):302–310.
   PubMed Web of Science ®Google Scholar
• Zhao L, Tian L, Wang S, et al. Levosimendan in rats decreases acute kidney injury after cardiopulmonary resuscitation by improving mitochondrial dysfunction. Transl Androl Urol. 2021;10(7):3010–3020.
   PubMed Web of Science ®Google Scholar
• Zhou C, Gong J, Chen D, et al. Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2016;67(3):408–416.
   PubMed Web of Science ®Google Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–1420.
   PubMed Web of Science ®Google Scholar
• Corrêa TD, Takala J, Jakob SM. Angiotensin II in septic shock. Crit Care. 2015;19(1):98.
   PubMedGoogle Scholar
• Wan L, Langenberg C, Bellomo R, et al. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13(6):R190.
   PubMed Web of Science ®Google Scholar
• NCT00711789. Angiotensin in septic kidney injury trial. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/results?cond=NCT00711789.
   Google Scholar
• McCullough PA, Bennett-Guerrero E, Chawla LS, et al. ABT-719 for the prevention of acute kidney injury in patients undergoing high-risk cardiac surgery: a randomized phase 2b clinical trial. J Am Heart Assoc. 2016;58: https://doi.org/10.1161/JAHA.116.003549
   Google Scholar
• NCT01897519. A safety and efficacy trial of multiple dosing regimens of ABT-719 for the prevention of acute kidney injury in subjects undergoing high risk surgery. [cited 2021 Sep 1.] https://clinicaltrials.gov/ct2/show/NCT01897519.
   Google Scholar
• Yang S, Li A, Wang J, et al. Vitamin D receptor: a novel therapeutic target for kidney diseases. Curr Med Chem. 2018;25(27):3256–3271.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim SC, Ko YS, et al. Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury. Biochem Biophys Res Commun. 2014;444(2):121–127.
   PubMed Web of Science ®Google Scholar
• Mohammed MA, Aboulhoda BE, Mahmoud RH. Vitamin D attenuates gentamicin-induced acute renal damage via prevention of oxidative stress and DNA damage. Hum Exp Toxicol. 2019;38(3):321–335.
   PubMed Web of Science ®Google Scholar
• Du J, Jiang S, Hu Z, et al. Vitamin D receptor activation protects against lipopolysaccharide-induced acute kidney injury through suppression of tubular cell apoptosis. Am J Physiol Renal Physiol. 2019;316(5):1068–1077.
   PubMed Web of Science ®Google Scholar
• Gurel A, Atli H, Kaya N, et al. Effects of vitamin D on kidney histology and trpv1 channels in doxorubicin-induced nephropathy. Int J Clin Exp Med. 2015;8(8):13548–13555.
   PubMed Web of Science ®Google Scholar
• El-Magd NF A, Eraky SM. The molecular mechanism underlining the preventive effect of vitamin D against hepatic and renal acute toxicity through the NrF2/ BACH1/ HO-1 pathway. Life Sci. 2020;244:117331.
   PubMed Web of Science ®Google Scholar
• NCT02869919. Vitamin D in critically Ill patients with acute kidney injury (VID-AKI). [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT02869919.
   Google Scholar
• Peters E, Ergin B, Kandil A, et al. Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury. Toxicol Appl Pharmacol. 2016;313:88–96.
   PubMed Web of Science ®Google Scholar
• Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-Day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. Jama. 2018;320(19):1998–2000.
   PubMed Web of Science ®Google Scholar
• Iwakura T, Zhao Z, Marschner JA, et al. Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration. Nephrol Dial Transplant. 2019;34(10):1669–1680.
   PubMed Web of Science ®Google Scholar
• Zhuge F, Ni Y, Nagashimada M, et al. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes. 2016;65(10):2966–2979.
   PubMed Web of Science ®Google Scholar
• Wu TJ, Hsieh YJ, Lu CW, et al. Linagliptin protects against endotoxin-induced acute kidney injury in rats by decreasing inflammatory cytokines and reactive oxygen species. Int J Mol Sci. 2021;22(20). DOI:https://doi.org/10.3390/ijms222011190.
   Google Scholar
• Takagaki Y, Shi S, Katoh M, et al. Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice. Sci Rep. 2019;9(1):7519.
   PubMed Web of Science ®Google Scholar
• Iwakura T, Fukasawa H, Kitamura A, et al. Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: a retrospective study. PloS one. 2020;15(2):e0229377.
   PubMed Web of Science ®Google Scholar
• Chandraker A, Takada M, Nadeau KC, et al. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int. 1997;52(6):1678–1684.
   PubMed Web of Science ®Google Scholar
• Mirzoeva S, Paunesku T, Wanzer MB, et al. Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice. PloS one. 2014;9(7):e101161.
   PubMed Web of Science ®Google Scholar
• NCT03403751. Phase 3 study of reltecimod vs placebo in patients with sepsis-associated acute kidney injury. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT03403751.
   Google Scholar
• Xu DP, Wells WW. alpha-Lipoic acid dependent regeneration of ascorbic acid from dehydroascorbic acid in rat liver mitochondria. J Bioenerg Biomembr. 1996;28(1):77–85.
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–2731.
   PubMed Web of Science ®Google Scholar
• Kang KP, Kim DH, Jung YJ, et al. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant. 2009;24(10):3012–3020.
   PubMed Web of Science ®Google Scholar
• Ambrosi N, Arrosagaray V, Guerrieri D, et al. α-lipoic acid protects against ischemia-reperfusion injury in simultaneous kidney-pancreas transplantation. Transplantation. 2016;100(4):908–915.
   PubMed Web of Science ®Google Scholar
• Suh SH, Lee KE, Kim IJ, et al. Alpha-lipoic acid attenuates lipopolysaccharide-induced kidney injury. Clin Exp Nephrol. 2015;19(1):82–91.
   PubMed Web of Science ®Google Scholar
• NCT01978405. Short-term alpha lipoic acid therapy for prevention of contrast-induced acute kidney injury and endothelial dysfunction in type 2 diabetes. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01978405.
   Google Scholar
• Trujillo J, Chirino YI, Molina-Jijón E, et al. Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol. 2013;1(1):448–456.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Lee RJ, et al. Nano encapsulated curcumin: and its potential for biomedical applications. Int J Nanomedicine. 2020;15:3099–3120.
   PubMed Web of Science ®Google Scholar
• Topcu-Tarladacalisir Y, Sapmaz-Metin M, Karaca T. Curcumin counteracts cisplatin-induced nephrotoxicity by preventing renal tubular cell apoptosis. Ren Fail. 2016;38(10):1741–1748.
   PubMed Web of Science ®Google Scholar
• He L, Peng X, Zhu J, et al. Protective effects of curcumin on acute gentamicin-induced nephrotoxicity in rats. Can J Physiol Pharmacol. 2015;93(4):275–282.
   PubMed Web of Science ®Google Scholar
• Hu JB, Li SJ, Kang XQ, et al. CD44-targeted hyaluronic acid-curcumin prodrug protects renal tubular epithelial cell survival from oxidative stress damage. Carbohydr Polym. 2018;193:268–280.
   PubMed Web of Science ®Google Scholar
• NCT01225094. Curcumin to prevent complications after elective abdominal aortic aneurysm (AAA) repair. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01225094.
   Google Scholar
• Bloomer SA, Brown KE, Kregel KC. Renal iron accumulation and oxidative injury with aging: effects of treatment with an iron chelator. J Gerontol A Biol Sci Med Sci. 2020;75(4):680–684.
   PubMed Web of Science ®Google Scholar
• NCT01391520. Efficacy and safety of deferiprone in patients with chronic kidney disease undergoing a cardiac catheterization and receiving contrast agent. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01391520
   Google Scholar
• NCT01146925. Deferiprone for the prevention of contrast-induced acute kidney injury. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01146925.
   Google Scholar
• NCT00870883. N-acetylcysteine plus deferoxamine for patients with hypotension. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT00870883
   Google Scholar
• Zhang DY, Liu H, He T, et al. Biodegradable self-assembled ultrasmall nanodots as reactive oxygen/nitrogen species scavengers for theranostic application in acute kidney injury. Small. 2021;17(8):e2005113.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao Y, Lei M, et al. Remote ischemic preconditioning to prevent acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2021;8:601470.
   PubMed Web of Science ®Google Scholar
• NCT03699696. A pilot analysis of the association between anesthesia induction dosing and AKI in the elderly population. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT03699696
   Google Scholar
• NCT02009280. A comparison of propofol based total intravenous anesthesia and sevoflurane based balanced anesthesia on renal protection during lung transplantation under extracorporeal membrane oxygenation - A prospective, randomized trial. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT02009280
   Google Scholar
• Sun T, Jiang D, Rosenkrans ZT, et al. A melanin-based natural antioxidant defense nanosystem for theranostic application in acute kidney injury. Adv Funct Mater. 2019;29(48). DOI:https://doi.org/10.1002/adfm.201904833.
   Google Scholar
• Ni D, Jiang D, Kutyreff CJ, et al. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun. 2018;9(1):5421.
   PubMedGoogle Scholar
• Rosenkrans ZT, Sun T, Jiang D, et al. Selenium-doped carbon quantum dots act as broad-spectrum antioxidants for acute kidney injury management. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2020;7(12):2000420.
   PubMedGoogle Scholar
• Hahn J, Wickham SF, Shih WM, et al. Addressing the instability of DNA nanostructures in tissue culture. ACS nano. 2014;8(9):8765–8775.
   PubMed Web of Science ®Google Scholar
• Du Y, Jiang Q, Beziere N, et al. DNA-nanostructure-gold-nanorod hybrids for enhanced in vivo optoacoustic imaging and photothermal therapy. Adv Mater. 2016;28(45):10000–10007.
   PubMed Web of Science ®Google Scholar
• Jiang D, Ge Z, Im HJ, et al. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng. 2018;2(11):865–877.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang H, Ge Z, et al. Treating acute kidney injury with antioxidative black phosphorus nanosheets. Nano Lett. 2020;20(2):1447–1454.
   PubMed Web of Science ®Google Scholar
• Zhang DY, Liu H, Zhu KS, et al. Prussian blue-based theranostics for ameliorating acute kidney injury. J Nanobiotechnology. 2021;19(1):266.
   PubMed Web of Science ®Google Scholar
• Hershberger KA, Martin AS, Hirschey MD. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol. 2017;13(4):213–225.
   PubMed Web of Science ®Google Scholar
• Tran MT, Zsengeller ZK, Berg AH, et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. 2016;531(7595):528–532.
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang SR, Huang XZ, et al. Nicotinamide mononucleotide, an NAD(+) precursor, rescues age-associated susceptibility to AKI in a Sirtuin 1-dependent manner. J Am Soc Nephrol. 2017;28(8):2337–2352.
   PubMed Web of Science ®Google Scholar
• NCT02701127. Molecular effects of vitamin B3 (Niacinamide) in acute kidney injury. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT02701127.
   Google Scholar
• Miyabe Y, Sekiya S, Sugiura N, et al. Renal subcapsular transplantation of hepatocyte growth factor-producing mesothelial cell sheets improves ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2019;317(2):F229–f239.
   PubMed Web of Science ®Google Scholar
• Zhou D, Tan RJ, Lin L, et al. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int. 2013;84(3):509–520.
   PubMed Web of Science ®Google Scholar
• Mungunsukh O, McCart EA, Day RM. Hepatocyte growth factor isoforms in tissue repair, cancer, and fibrotic remodeling. Biomedicines. 2014;2(4):301–326.
   PubMedGoogle Scholar
• Farrell J, Kelly C, Rauch J, et al. HGF induces epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2 and ISG15 pathways. J Proteome Res. 2014;13(6):2874–2886.
   PubMed Web of Science ®Google Scholar
• Benoit SW, Devarajan P. Acute kidney injury: emerging pharmacotherapies in current clinical trials. Pediatr Nephrol. 2018;33(5):779–787.
   PubMed Web of Science ®Google Scholar
• NCT01286727. Study to improve renal function after kidney transplantation. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01286727.
   Google Scholar
• NCT02474667. Reduce the severity of DGF in recipients of a deceased donor kidney. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT02474667
   Google Scholar
• NCT02771509. Study to prevent acute kidney injury after cardiac surgery involving cardiopulmonary bypass. [cited 2021 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT02771509
   Google Scholar
• Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18(3):396–404.
   PubMed Web of Science ®Google Scholar
• Aoki H, Fujii M, Imamura T, et al. Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci. 2001;114(Pt 8):1483–1489.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Chertow GM, McCullough PA, et al. Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018;29(2):670–679.
   PubMed Web of Science ®Google Scholar
• Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379–1387.
   PubMed Web of Science ®Google Scholar
• Takasaki T, Hagihara K, Satoh R, et al. More than just an immunosuppressant: the emerging role of FTY720 as a novel inducer of ROS and apoptosis. Oxid Med Cell Longev. 2018;2018:4397159.
   PubMed Web of Science ®Google Scholar
• Bajwa A, Rosin DL, Chroscicki P, et al. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol. 2015;26(4):908–925.
   PubMed Web of Science ®Google Scholar
• Cao JY, Wang B, Tang TT, et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics. 2021;11(11):5248–5266.
   PubMed Web of Science ®Google Scholar
• Chen S, Yao Y, Lin F, et al. MiR-424 is over-expressed and attenuates ischemia-reperfusion kidney injury via p53 and death receptor 6 pathway. Am J Transl Res. 2019;11(4):1965–1979.
   PubMed Web of Science ®Google Scholar
• Ramos AM, González-Guerrero C, Sanz A, et al. Designing drugs that combat kidney damage. Expert Opin Drug Discov. 2015;10(5):541–556.
   PubMed Web of Science ®Google Scholar
• NCT02610283. A study to evaluate efficacy and safety of QPI-1002 for prevention of acute kidney injury following cardiac surgery. https://clinicaltrials.gov/ct2/show/NCT02610283.
   Google Scholar
• NCT03510897. QPI-1002 Phase 3 for prevention of major adverse kidney events (MAKE) in subjects at high risk for AKI following cardiac surgery. https://clinicaltrials.gov/ct2/show/NCT03510897.
   Google Scholar
• Wu YL, Li HF, Chen HH, et al. MicroRNAs as biomarkers and therapeutic targets in inflammation- and ischemia-reperfusion-related acute renal injury. Int J Mol Sci. 2020;21(18):6738.
   Web of Science ®Google Scholar
• Zhang Y, Huang H, Liu W, et al. Endothelial progenitor cells-derived exosomal microRNA-21-5p alleviates sepsis-induced acute kidney injury by inhibiting RUNX1 expression. Cell Death Dis. 2021;12(4):335.
   PubMed Web of Science ®Google Scholar
• Chiba T, Cerqueira DM, Li Y, et al. Endothelial-derived miR-17∼92 promotes angiogenesis to protect against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2021;32(3):553–562.
   PubMed Web of Science ®Google Scholar
• Zaborowski MP, Balaj L, Breakefield XO, et al. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015;65(8):783–797.
   PubMed Web of Science ®Google Scholar
• NCT02315183. An observational case control study to identify the role of MV and MV derived micro-RNA in post cardiac surgery AKI (MaRACAS). https://clinicaltrials.gov/ct2/show/NCT02315183.
   Google Scholar
• Battogtokh G, Choi YS, Kang DS, et al. Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives. Acta Pharm Sin B. 2018;8(6):862–880.
   PubMed Web of Science ®Google Scholar
• Mercer JR, Yu E, Figg N, et al. The mitochondria-targeted antioxidant mitoQ decreases features of the metabolic syndrome in ATM±/ApoE-/- mice. Free Radic Biol Med. 2012;52(5):841–849.
   PubMed Web of Science ®Google Scholar
• Lowes DA, Thottakam BM, Webster NR, et al. The mitochondria-targeted antioxidant mitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med. 2008;45(11):1559–1565.
   PubMed Web of Science ®Google Scholar
• Jankauskas SS, Andrianova NV, Alieva IB, et al. Dysfunction of kidney endothelium after ischemia/reperfusion and its prevention by mitochondria-targeted antioxidant. Biochem Biokhimiia. 2016;81(12):1538–1548.
   PubMed Web of Science ®Google Scholar
• Oikawa Y, Izumi R, Koide M, et al. Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PloS one. 2020;15(12):e0231064.
   PubMed Web of Science ®Google Scholar
• Matsuhashi T, Sato T, Kanno SI, et al. Mitochonic acid 5 (MA-5) facilitates ATP synthase oligomerization and cell survival in various mitochondrial diseases. EBioMedicine. 2017;20:27–38.
   PubMed Web of Science ®Google Scholar
• Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22(6):1041–1052.
   PubMed Web of Science ®Google Scholar
• Cho J, Won K, Wu D, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18(3):215–220.
   PubMed Web of Science ®Google Scholar
• Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2006;98(4):1141–1148.
   PubMed Web of Science ®Google Scholar
• Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261.
   PubMed Web of Science ®Google Scholar
• NCT04194671. Clinical trial of mesenchymal stem cells in the treatment of severe acute kidney injury. https://clinicaltrials.gov/ct2/show/NCT04194671.
   Google Scholar
• NCT01275612. Mesenchymal stem cells in cisplatin-induced acute renal failure in patients with solid organ cancers (CIS/MSC08). https://clinicaltrials.gov/ct2/show/NCT01275612.
   Google Scholar
• Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. J Am Soc Nephrol. 2018;29(1):260–267.
   PubMed Web of Science ®Google Scholar
• Hu JB, Kang XQ, Liang J, et al. E-selectin-targeted sialic acid-PEG-dexamethasone micelles for enhanced anti-Inflammatory efficacy for acute kidney injury. Theranostics. 2017;7(8):2204–2219.
   PubMed Web of Science ®Google Scholar
• Wang DW, Li SJ, Tan XY, et al. Engineering of stepwise-targeting chitosan oligosaccharide conjugate for the treatment of acute kidney injury. Carbohydr Polym. 2021;256:117556.
   PubMed Web of Science ®Google Scholar